ICCS Advocacy Committee
|
|
- Regina Kelly
- 6 years ago
- Views:
Transcription
1 January 12, 2015 U.S. Department of Health and Human Services Food and Drug Administration Center for Devices and Radiological Health Office of In Vitro Diagnostics and Radiological Health Division of Immunology and Hematology Hematology Branch RE: (1) [FDA D- 1351]Flow Cytometric Devices: Draft Guidance for Industry and Food and Drug Administration Staff To whom it may concern: We are writing on behalf of the International Clinical Cytometry Society (ICCS) to comment on the above- referenced draft guidance. ICCS is a non- profit professional organization dedicated to promoting education and advancements world- wide in the application of flow cytometry to clinical needs ( It is the largest organization of its kind and its membership is comprised of practicing physicians, scientists, medical technologists, and laboratory personnel focused on promoting the highest standards of clinical practice in this field. Although the majority of ICCS members are not the specified target audience, we do consider ourselves to be crucial stakeholders affected by this guidance. Furthermore, should the recently published Draft Guidance for Industry, Food and Drug Administration Staff, and Clinical Laboratories: Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs) eventually be adopted, ICCS members would become de facto manufacturers of cytometric devices. We thank you for the opportunity to contribute to this important document and look forward to ongoing engagement with the FDA. Our overarching concerns around this guidance are essentially all related to its clarity and timeliness, particularly as regards the distinction between qualitative (i.e. leukemia/lymphoma testing) and quasi- quantitative (i.e. CD34 enumeration)assays. An excellent summary of this distinction and the many fundamental ways in which these types of assays differ may be found in Wood et al. s 2013 Validation of cell- based fluorescence assays: practice guidelines from the ICSH and ICCS - part V - assay performance criteria. (2) Given that the guidance does not include this reference, any of the other related and co- published ICSH/ICCS fluorescence assay validation references (3-8), or indeed any reference more recent than 2007, it is not surprising that the guidance content is somewhat dated and does not always reflect current thinking or practice regarding flow cytometry. The guidance also ignores many technological advances over the last decade. We have included a number of more recent references at the end of this letter, and urge you to consider them when drafting the next version of this guidance.
2 Insofar as guidance specifics are concerned, we summarize here a number of issues. We start with what we consider to be the most important omissions from the current draft and subsequently address statements that we find to be inaccurate, incomplete, or unnecessarily prescriptive. Note that we use line numbers to reference specific points of the draft guidance, as the section labeling format is not applied uniformly across the document, and does not correspond to the Table of Contents. As indicated earlier in this letter, we consider the distinction between qualitative and quasi- quantitative assays to be of paramount importance (9), and strongly encourage emphasis of this concept in the guidance. Separate sections of the guidance (or possibly even separate guidance documents) addressing the two types of assays would be particularly helpful, as certain concepts such as linearity, reference ranges, and reference intervals are not relevant to qualitative assays. Similarly, the guidance regarding qualitative assays needs to acknowledge that limit of detection (LOD) and limit of blank (LOB) for qualitative assays such a leukemia/lymphoma immunophenotyping is closely linked to the phenotype of a specific patient s aberrant/malignant population (as well as to the number of simultaneously- assessed parameters and the reagents used), and the patient- to- patient variability is such that LOD/LOB is very nearly patient/sample- specific. Consequently, the cut- off attainable for one patient may not be appropriate for another patient. This issue becomes especially relevant in the case of minimal residual disease (MRD). The section entitled Enumeration of Rare Events (lines ), cites suggested target detection levels from the 2006 Bethesda International Consensus Recommendations on the Immunophenotypic Analysis of Hematolymphoid Neoplasia by Flow Cytometry (10) as follows: B cell, 0.1%; T cell, 1%; Myelomonocytic, 0.5%; and Plasma cell, 0.1%. The guidance appears to suggest that these levels might be informative for minimal residual disease. These targets, however, were not intended to be used in the MRD context but instead reflected the experience of the authors when surveyed regarding typical lineage- specific limits of detection when using their usual reagent combinations and their own, laboratory- developed methods for routine diagnosis and monitoring of patients with hematolymphoid neoplasms. We do not recommend use of these ballpark figures as benchmarks for minimal residual disease assays, and instead encourage the use of more rigorous and clinically- relevant, disease- specific decision points as documented in the extensive medical literature on this topic. (11-18) Other statements that we find to be inaccurate, incomplete, or unnecessarily prescriptive include but are not limited to the following: 1. Specimen and Data Analysis, line 480 The use of paired isotype matched control antibodies is suggested here and elsewhere (lines 536 and 895) in the guidance. A large body of literature describes the limitations and failings of isotype controls (19,20) and we do not recommend their use. This section also ignores Fluorescence- Minus- One controls for gating (21) as well as newer computational data analysis tools such as probability state modeling (22,23).
3 2. Analytical Specificity: Reagents, lines This section suggests the use of Western blots to evaluate monoclonal antibodies without noting that Western blots present antigens in their denatured format. Only linear epitopes can therefore be assessed using this technique; epitopes that are presented conformationally on the cell surface will not be recognized by Western blot (24). This section also states that specificity should be demonstrated by showing that the binding of each antibody in the multi- color reagent cocktail (single parameter analysis) is equal to that of the individual antibody- conjugates when used to stain the antigen expressing cells at the same concentration as in the final cocktail. From a practical perspective this requirement may not be possible to meet, as some antigens cannot be reliably detected by themselves. There is no discussion regarding reagents for defining signal to noise ratio, a basic but important aspect of many flow cytometric assays, nor is there any discussion of reagent optimization (25). Non- antibody reagents for flow cytometry assays are not discussed. 3. Detection Sensitivity, lines , Figure 1 The procedure described in this lengthy and prescriptive section is not referenced, and is not widely used by the flow cytometry community. 4. Linear Range, lines We suggest inclusion of guidance for demonstration of linearity for assays measuring antigen density (8,26). 5. Repeatability & Reproducibility, lines These sections state that repeatability and reproducibility should be demonstrated using clinical specimens that are prepared 20 times and analyzed in batch fashion and further indicate that this testing be carried out on blood, bone marrow, lymph nodes, or other specimen types. Not only is this suggestion not even remotely feasible given the constraints of patient sample size (27,28), it is unnecessary: recent publications demonstrate that 3 to 6 replicates over three analytical runs are adequate to demonstrate repeatability and reproducibility (2,8,29). Similarly, patient samples that span the reportable range from low, medium and high are essentially irrelevant in the context of qualitative assays for leukemia/lymphoma. We suggest that the statement Where specimen availability and stability permit, you should include at least 20 days and at least 2 replicates per day be deleted, as there are no instances in which specimen availability and stability would permit this testing, and currently no clinical setting to which it would apply. In addition to the above specific issues, we would like to make several additional points regarding revision of this draft guidance. First, recent advances in flow cytometry technology should be discussed, including cytometers with greater than 4- color capacity, cytometers with digital (rather than analog) signal processing, cytometers and assays that do not require compensation, new fluorophors, and new blood collection tubes. Note also that Clinical Laboratory Standards Institutes (CLSI) has adopted the term measurand to replace analyte (30); we encourage the use of current
4 terminology. Reference ranges in general are similarly no longer considered to be relevant by the clinical laboratory community (31). In conclusion, we would like to thank the FDA for the opportunity to provide constructive criticism on this draft guidance. We encourage you to take advantage of the wealth of experience and expertise within the clinical flow cytometry community in general, and particularly within the International Clinical Cytometry Society. Please do not hesitate to contact any of us for clarification or assistance regarding this letter. We look forward to working together with the FDA on future versions of this guidance. Best regards, The ICCS Advocacy Bruce Davis, Jeannine Holden, Jerry Hussong, Virginia Litwin, Teri Oldaker, Angela Salazar, Elizabeth Stone, Paul K Wallace, paul.wallace@roswellpark.org
5 References ICCS Advocacy 1. FDA D FD Flow Cytometric Devices Draft Guidance for Industry and Food and Drug Administration Staff. -!documentdetail;d=fda D Wood B, Jevremovic D, Bene MC, Yan M, Jacobs P, Litwin V, Group IIW. Validation of cell- based fluorescence assays: practice guidelines from the ICSH and ICCS - part V - assay performance criteria. Cytometry B Clin Cytom 2013;84: Barnett D, Louzao R, Gambell P, De J, Oldaker T, Hanson CA, Group IIW. Validation of cell- based fluorescence assays: practice guidelines from the ICSH and ICCS - part IV - postanalytic considerations. Cytometry B Clin Cytom 2013;84: Bene MC, Marti GE. ICSH/ICCS practice guidelines special issue. Cytometry B Clin Cytom 2013;84: Davis BH, Dasgupta A, Kussick S, Han JY, Estrellado A, Group IIW. Validation of cell- based fluorescence assays: practice guidelines from the ICSH and ICCS - part II - preanalytical issues. Cytometry B Clin Cytom 2013;84: Davis BH, McLaren CE, Carcio AJ, Wong L, Hedley BD, Keeney M, Curtis A, Culp NB. Determination of optimal replicate number for validation of imprecision using fluorescence cell- based assays: proposed practical method. Cytometry B Clin Cytom 2013;84: Davis BH, Wood B, Oldaker T, Barnett D. Validation of cell- based fluorescence assays: practice guidelines from the ICSH and ICCS - part I - rationale and aims. Cytometry B Clin Cytom 2013;84: Tanqri S, Vall H, Kaplan D, Hoffman B, Purvis N, Porwit A, Hunsberger B, Shankey TV, Group IIW. Validation of cell- based fluorescence assays: practice guidelines from the ICSH and ICCS - part III - analytical issues. Cytometry B Clin Cytom 2013;84: Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, Keller S, Weinryb I, Green M, Duan L and others. Fit- for- purpose method development and validation for successful biomarker measurement. Pharm Res 2006;23: Wood BL, Arroz M, Barnett D, DiGiuseppe J, Greig B, Kussick SJ, Oldaker T, Shenkin M, Stone E, Wallace P Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin Cytom 2007;72 Suppl 1:S Paiva B, Vidriales M- B, Cervero J, Mateo G, Perez JJ, Montalban MA, Sureda A, Montejano L, Gutierrez NC, De Coca AG and others. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008;112: Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro- Coy N, Drayson MT, Feyler S and others. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on
6 outcome in the Medical Research Council Myeloma IX Study. Journal of Clinical Oncology 2013;31: Roussel M, Lauwers- Cances V, Robillard N, Hulin C, Leleu X, Benboubker L, Marit G, Moreau P, Pegourie B, Caillot D and others. Front- line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome. Journal of Clinical Oncology 2014;32: Jaso JM, Wang SA, Jorgensen JL, Lin P. Multi- color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future. Bone Marrow Transplant 2014;49: Paiva B, Chandia M, Puig N, Vidriales MB, Perez JJ, Lopez- Corral L, Ocio EM, Garcia- Sanz R, Gutierrez NC, Jimenez- Ubieto A and others. The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapse multiple myeloma. Haematologica Rawstron AC, Bottcher S, Letestu R, Villamor N, Fazi C, Kartsios H, de Tute RM, Shingles J, Ritgen M, Moreno C and others. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia 2013;27: Coustan- Smith E, Campana D. Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testing. Best Pract Res Clin Haematol 2010;23: Bar M, Wood BL, Radich JP, Doney KC, Woolfrey AE, Delaney C, Appelbaum FR, Gooley TA. Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia. Leuk Res Treatment 2014;2014: Stetler- Stevenson M, Ahmad E, Barnett D, Braylan RC, DiGiuseppe JA, Marti GE, Menozzi D, Oldaker TA, Orfao de Matos A, Rabellino E and others. Clinical Flow Cytometric Analysis of Neoplastic Hematolymphoid Cells; Approved Guideline- Second Edition. CLSI document H43- A2. Wayne, PA: Clinical and Laboratory Standards Institute; Stelzer GT, Marti G, Hurley A, McCoy P, Jr., Lovett EJ, Schwartz A. U.S.- Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry 1997;30: Roederer M. Compensation in flow cytometry. Curr Protoc Cytom 2002;Chapter 1:Unit Herbert DJ, Miller DT, Bruce Bagwell C. Automated analysis of flow cytometric data for CD34+ stem cell enumeration using a probability state model. Cytometry B Clin Cytom 2012;82: Pedreira CE, Costa ES, Lecrevisse Q, van Dongen JJ, Orfao A, EuroFlow C. Overview of clinical flow cytometry data analysis: recent advances and future challenges. Trends Biotechnol 2013;31: Gallagher S, Winston SE, Fuller SA, Hurrell JG. Immunoblotting and immunodetection. Curr Protoc Cell Biol 2011;Chapter 6:Unit6 2.
7 25. Tario Jr. JD, Wallace PK. Reagents and Cell Staining for Immunophenotyping by Flow Cytometry. In: McManus LM, Mitchell RN, editors. Pathobiology of Human Disease. San Diego: Elsevier; p Maher KJ, Klimas NG, Hurwitz B, Schiff R, Fletcher MA. Quantitative fluorescence measures for determination of intracellular perforin content. Clin Diagn Lab Immunol 2002;9: Litwin V, Green C The role of biomarkers in clinical trials and the fit- for- purpose method validation approach. erences/ucm pdf. 28. Oldaker T LDTs in Flow Cytometry: ICSH/ICCS guidelines for validation of fluorescent cell- based diagnostic testing. erences/ucm pdf. 29. O'Hara DM, Xu Y, Liang Z, Reddy MP, Wu DY, Litwin V. Recommendations for the validation of flow cytometric testing during drug development: II assays. J Immunol Methods 2011;363: QC, Westgard Glossary of QC terms Horowitz GL, Altaie S, Boyd JC, Ceriotti F, Garg U, Horn P, Pesce A, Sine HE, Zakowski J. Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline third edition. CLSI document EP28- A3C. Wayne, PA; 2010.
MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods
REGULAR ARTICLE MRD detection in multiple myeloma: comparison between MSKCC 1-color single-tube and EuroFlow 8-color 2-tube methods Mikhail Roshal, 1 Juan A. Flores-Montero, 2-4 Qi Gao, 1 Maesa Koeber,
More informationManaging Specimen Stability for Robust Flow Cytometric Clinical Biomarker Assays
Managing Specimen Stability for Robust Flow Cytometric Clinical Biomarker Assays Dianna Wu, Richard Wnek Molecular Biomarkers & Diagnostics Merck Co., Inc 2014 AAPS Annual Meeting San Diego, CA (Fluorescent
More informationThe Journey Towards Standardization in Validation of Fluorescent Cell-Based Assays
The Journey Towards Standardization in Validation of Fluorescent Cell-Based Assays Teri Oldaker, CLS, Ccy Genoptix Medical Laboratory Flow Cytometry Workshop ISCT 2015, Las Vegas, NV Objectives Background
More informationQuality Control in Flow. Dr David Westerman Head of Haematopathology Peter MacCallum Cancer Centre
Quality Control in Flow Dr David Westerman Head of Haematopathology Peter MacCallum Cancer Centre Aims Quality Assurance Quality Control Literature In house competencies SHOT DATA 1996-2009 Ref: SHOT Annual
More informationValidation of Cell-based Fluorescence Assays: Practice Guidelines from the ICSH and ICCS Part V Assay Performance Criteria
Cytometry Part B (Clinical Cytometry) 84B:315 323 (2013) Validation of Cell-based Fluorescence Assays: Practice Guidelines from the ICSH and ICCS Part V Assay Performance Criteria Brent Wood, 1 Dragan
More informationAugust 2017 Changes. Flow Cytometry Checklist. CAP Accreditation Program
August 2017 Changes Flow Cytometry Checklist CAP Accreditation Program College of American Pathologists 325 Waukegan Road Northfield, IL 60093-2750 www.cap.org 08.21.2017 Disclaimer and Copyright Notice
More informationBringing the EuroFlow Concept
Bringing the EuroFlow Concept Cytognos - EuroFlow Supporting Company Company Overview Cytognos provides through worldwide distribution a broad range of reagents and software for flow cytometry applications
More informationCLEARLLAB LS LYMPHOID SCREEN REAGENT
CLEARLLAB LS LYMPHOID SCREEN REAGENT CE MARKED ANTIBODY COMBINATION FOR LEUKEMIA / LYMPHOMA ANALYSIS Because Your Patient is Her Everything BECAUSE YOUR PATIENT IS HER EVERYTHING ClearLLab LS Lymphoid
More informationStandardization of Minimal Residual Disease Testing in Multiple Myeloma
Standardization of Minimal Residual Disease Testing in Multiple Myeloma Linda B. Baughn 1 and Michael A. Linden 2 * Multiple myeloma (MM) 3 is an incurable neoplasm of the bone marrow characterized by
More informationSingle Tube, Six-Color Flow Cytometric Analysis Is a Sensitive and Cost-Effective Technique for Assaying Clonal Plasma Cells
Hematopathology / Flow Cytometric Analysis of Clonal Plasma Cells Single Tube, Six-Color Flow Cytometric Analysis Is a Sensitive and Cost-Effective Technique for Assaying Clonal Plasma Cells Derek K. Marsee,
More informationFlow Cytometry Method Validation Protocols
Flow Cytometry Method Validation Protocols Nithianandan Selliah, 1 Steven Eck, 2 Cherie Green, 3 Teri Oldaker, 4 Jennifer Stewart, 5 Alessandra Vitaliti, 6 and Virginia Litwin 7,8 1 Covance Central Laboratories,
More informationNovel Lymphocyte Screening Tube Using Dried Monoclonal Antibody Reagents
Cytometry Part B (Clinical Cytometry) 88B:361 370 (2015) Original Article Novel Lymphocyte Screening Tube Using Dried Monoclonal Antibody Reagents Benjamin D. Hedley, 1 * Michael Keeney, 1 Janice Popma,
More informationImmunophenotyping of Peripheral Blood and Bone Marrow Cells by Flow Cytometry *Akanni EO and # Palini A.
Immunophenotyping of Peripheral Blood and Bone Marrow Cells by Flow Cytometry *Akanni EO and # Palini A. * Department of Haematology & Blood Transfusion,College of Health Science, Ladoke Akintola University
More informationReport of the Clinical Practice Task Force Survey of the Clinical Cytometry Society
Cytometry (Communications in Clinical Cytometry) 46:177 183 (2001) Forum Report of the Clinical Practice Task Force Survey of the Clinical Cytometry Society J. Philip McCoy, Jr. 1 and Bruce H. Davis 2
More informationKey terms: flow cytometry; reagents; reporting; consensus; optimal
Cytometry Part B (Clinical Cytometry) 72B:S14 S22 (2007) 2006 Bethesda International Consensus Recommendations on the Immunophenotypic Analysis of Hematolymphoid Neoplasia by Flow Cytometry: Optimal Reagents
More informationDesigning and Validating a Multicolor Flow Cytometry Assay. Brent Wood MD PhD Department of Laboratory Medicine University of Washington
Designing and Validating a Multicolor Flow Cytometry Assay Brent Wood MD PhD Department of Laboratory Medicine University of Washington Specimen Handling Sample Requirements 5 ml Peripheral blood (EDTA,
More informationFlow Cytometry in the Diagnosis of Hematopoietic Neoplasia. Brent Wood MD, PhD Professor, Laboratory Medicine University of Washington, Seattle
Flow Cytometry in the Diagnosis of Hematopoietic Neoplasia Brent Wood MD, PhD Professor, Laboratory Medicine University of Washington, Seattle 1 Flow Cytometer 2 The Power of Flow Cytometry Single cell
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: flow_cytometry 1/1/2019 N/A 1/1/2020 1/1/2019 Policy Effective April 1, 2019 Description of Procedure or
More informationFlow Cytometric Devices Draft Guidance for Industry and Food and Drug Administration Staff DRAFT GUIDANCE
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 36 Flow Cytometric Devices Draft Guidance for Industry and Food and Drug Administration Staff DRAFT GUIDANCE This guidance document
More informationImmunophenotyping, Sheffield S10 2JF, UK 3 Department of Flow Cytometry, Maryam Saber Genoptix Medical Laboratory, Carlsbad, California
Cytometry Part B (Clinical Cytometry) 94B:67 81 (2018) Original Article ICCS/ESCCA Consensus Guidelines to detect GPI-deficient cells in Paroxysmal Nocturnal Hemoglobinuria (PNH) and related Disorders
More informationRuud Hulspas, Mike Keeney, Ben Hedley and Andrea Illingworth
Sponsored and reviewed by ICCS Quality and Standards Committee Title: Quality of Reagents Monoclonal Antibodies Written by: Date: March 6, 2018 Ruud Hulspas, Mike Keeney, Ben Hedley and Andrea Illingworth
More informationAnalytical Method Validation: Perspectives from the AAPS Flow Cytometry Action Programming Committee
Analytical Method Validation: Perspectives from the AAPS Flow Cytometry Action Programming Committee Virginia Litwin, Ph.D., Principal Scientist, Hematology Department, Covance Founder and Chair Flow Cytometry
More informationDetermination of Optimal Replicate Number for Validation of Imprecision Using Fluorescence Cell-Based Assays: Proposed Practical Method
Cytometry Part B (Clinical Cytometry) 84B:329 337 (2013) Original Article Determination of Optimal Replicate Number for Validation of Imprecision Using Fluorescence Cell-Based Assays: Proposed Practical
More informationSAMPLE. Validation, Verification, and Quality Assurance of Automated Hematology Analyzers; Approved Standard Second Edition
June 2010 Validation, Verification, and Quality Assurance of Automated Hematology Analyzers; Approved Standard Second Edition This document provides guidance for the validation, verification, calibration,
More informationAccreditation in flow cytometry Discussion of guidelines. A. Gothot Liège University Hospital
Accreditation in flow cytometry Discussion of guidelines A. Gothot Liège University Hospital CH 2 OH O H H OH OH H OH H OH What should be done to support accreditation in flow cytometry? Recommendation
More informationVerification or validation, that is the question
Perspective Page 1 of 7 Verification or validation, that is the question Giorgia Antonelli 1, Andrea Padoan 1, Ada Aita 1, Laura Sciacovelli 2, Mario Plebani 1,2 1 U.O.C. of Laboratory Medicine, Department
More informationMaster. Flow Cytometry Checklist. CAP Accreditation Program
Master Flow Cytometry Checklist CAP Accreditation Program College of American Pathologists 325 Waukegan Road Northfield, IL 60093-2750 www.cap.org 08.21.2017 2 of 24 Disclaimer and Copyright Notice On-site
More informationUNDERSTANDING THE CLONOSEQ ASSAY
FOR HEALTHCARE PROVIDERS UNDERSTANDING THE CLONOSEQ ASSAY Clonality (ID) and Tracking (MRD) Reports clonoseq is an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies
More informationStrategies for Assessment of Immunotoxicology in Preclinical Drug Development
Strategies for Assessment of Immunotoxicology in Preclinical Drug Development Rebecca Brunette, PhD Scientist, Analytical Biology SNBL USA Preclinical Immunotoxicology The study of evaluating adverse effects
More informationQuality Control in Clinical Flow Cytometry
Clin Lab Med 27 (2007) 671 685 Quality Control in Clinical Flow Cytometry Teri A. Oldaker, CLS (NCA), ASCP (QCYM) Genzyme Genetics, 5300 McConnell Avenue, Los Angeles, CA 90066, USA Flow cytometry assays
More informationMaster. Flow Cytometry Checklist. CAP Accreditation Program
Master Flow Cytometry Checklist CAP Accreditation Program College of American Pathologists 325 Waukegan Road Northfield, IL 60093-2750 www.cap.org 08.17.2016 2 of 24 Disclaimer and Copyright Notice On-site
More informationCD22 (S-HCL-1) IVD. Table 1 Bottling concentrations. Monoclonal mouse anti-human reagent for identification of cells expressing CD22 antigen
2/2014 23-6995-02 IVD CD22 (S-HCL-1) Monoclonal mouse anti-human reagent for identification of cells expressing CD22 antigen Form Catalog No. FITC 337898 PE 337899 APC 333145 BD, BD Logo and all other
More informationLambda-APC-C750 Ref: CYT-LAC750
Lambda-APC-C750 Ref: CYT-LAC750 For In Vitro Diagnostic use INTENDED USE Lambda-APC-C750 is a polyclonal antibody (pab) labelled with the tandem allophycocyanine-c750 (APC- C750) and designed for use as
More informationTitration of Fluorochrome-Conjugated Antibodies for Labeling Cell Surface Markers on Live Cells
Titration of Fluorochrome-Conjugated Antibodies for Labeling Cell Surface Markers on Live Cells Ruud Hulspas 1 UNIT 6.29 1 Cytonome/ST, Boston, Massachusetts ABSTRACT Nonspecific antibody binding is best
More informationSAMPLE. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline Third Edition
October 2010 Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline Third Edition This document contains guidelines for determining reference values and
More informationCordone et al. Journal of Experimental & Clinical Cancer Research (2016) 35:49 DOI /s
Cordone et al. Journal of Experimental & Clinical Cancer Research (2016) 35:49 DOI 10.1186/s13046-016-0324-0 RESEARCH Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in
More informationValidation of Immunoassays for Biomarker Detection at Sequani.
White Paper Validation of Immunoassays for Biomarker Detection at Sequani. Brenda A Finney, PhD Principal Scientist, Biological Sciences, Sequani Limited This paper is intended to review the literature
More informationLABORATORY ASSESSMENT OF HAEMATOLOGY ONCOLOGY IMMUNOPHENOTYPING. First Edition Australasian Cytometry Society Laboratory Assessment Document
LABORATORY ASSESSMENT OF HAEMATOLOGY ONCOLOGY IMMUNOPHENOTYPING First Edition 2018 Australasian Cytometry Society Laboratory Assessment Document Paper-based publications This work is copyright. You may
More informationPrinciples of Minimal Residual Disease Detection for Hematopoietic Neoplasms by Flow Cytometry
Cytometry Part B (Clinical Cytometry) 90B:47 53 (2016) Review Principles of Minimal Residual Disease Detection for Hematopoietic Neoplasms by Flow Cytometry Brent L. Wood 1,2 * 1 Department of Laboratory
More informationSAMPLE. Evaluation of Total Analytical Error for Quantitative Medical Laboratory Measurement Procedures
2nd Edition EP21 Evaluation of Total Analytical Error for Quantitative Medical Laboratory Measurement Procedures This guideline provides manufacturers and end users with an understanding of concepts related
More informationAssessment of Minimal Residual Disease in Myeloma and the Need for a Consensus Approach
Cytometry Part B (Clinical Cytometry) 90B:21 25 (2016) Brief Communication Assessment of Minimal Residual Disease in Myeloma and the Need for a Consensus Approach Andy C. Rawstron, 1 * Bruno Paiva, 2,3,4
More informationRef: CYT-MM-MRD. For research use only
Distributed By: ALPCO 26-G Keewaydin Drive Salem, NH 03079 www.alpco.com P 800-592-5726 F 603-898-6854 Ref: CYT-MM-MRD For research use only MM-MRD VIALS ARE A LYOPHILIZED PRODUCT. READ CAREFULLY THE FOLLOWING
More informationCongreso Nacional del Laboratorio Clínico 2016
Técnicas de alta sensibilidad en la detección de enfermedad mínima residual en Mieloma Múltiple J. Flores-Montero, MD, PhD Departamento de Medicina, Servicio Central de Citometría, Centro de Investigación
More informationUse of Flow Cytometry in Clinical Practice
Section Editors: Denice Economou and Sandra E. Kurtin Use of Flow Cytometry in Clinical Practice DAWN M. BETTERS, PhD, RN From Case Western Reserve University, Cleveland, Ohio Author s disclosures of potential
More informationBD IntraSure Kit IVD. Cell fixation and permeabilization reagents. 50 tests per kit Catalog No
03/2015 23-8992-01 IVD BD IntraSure Kit Cell fixation and permeabilization reagents 50 tests per kit Catalog No. 641778 BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company.
More information2111: ALL Post-HCT. Add/ Remove/ Modify. Manual Section. Date. Description. Comprehensive Disease- Specific Manuals
2111: ALL Post-HCT The Acute Lymphoblastic Leukemia Post-HCT Data Form is one of the Comprehensive Report Forms. This form captures ALL-specific post-hct data such as: planned treatments post-hct, the
More informationCME/SAM. Limited Flow Cytometry Panels on Bone Marrow Specimens Reduce Costs and Predict Negative Cytogenetics
Limited Flow Cytometry Panels on Bone Marrow Specimens Reduce Costs and Predict Negative Cytogenetics Douglas G. Hoffmann, MD, and Burton H. Kim, MD From the Department of Pathology, Wellstar Health System,
More informationAssociation for Molecular Pathology Promoting Clinical Practice, Basic Research, and Education in Molecular Pathology
Association for Molecular Pathology Promoting Clinical Practice, Basic Research, and Education in Molecular Pathology 9650 Rockville Pike, Bethesda, Maryland 20814 Tel: 301-634-7939 Fax: 301-634-7990 Email:
More informationWhite Rose Research Online URL for this paper: Version: Accepted Version
This is a repository copy of Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/108927/
More informationCD7 (M-T701) IVD. Antibody purity is as follows. FITC: 5% free fluorophore at bottling, as measured by size-exclusion chromatography (SEC)
8/2013 23-6905-02 IVD CD7 (M-T701) Monoclonal mouse anti-human reagent for identification of cells expressing CD7 antigen Form Catalog No. FITC 332773 PE 332774 BD, BD Logo and all other trademarks are
More informationASSESSMENT OF CLINICAL FLOW CYTOMETRY LABORATORY PRACTICE. First Edition Australasian Cytometry Society Laboratory Assessment Document
ASSESSMENT OF CLINICAL FLOW CYTOMETRY LABORATORY PRACTICE First Edition 2018 Australasian Cytometry Society Laboratory Assessment Document Paper-based publications This work is copyright. You may reproduce
More informationA high recovery and high purity data analysis strategy for rare abnormal plasma cell events using the DuraClone RE PC Tube
APPLICATION NOTE A high recovery and high purity data analysis strategy for rare abnormal plasma cell events using the DuraClone RE PC Tube Dr Agnieszka Blum Charité Virchow Hospital, Stem Cell Facility,
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #70 (NQF 0379): Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY
More informationSAMPLE. Enumeration of Immunologically Defined Cell Populations by Flow Cytometry; Approved Guideline Second Edition
May 2007 Enumeration of Immunologically Defined Cell Populations by Flow Cytometry; Approved Guideline Second Edition This document provides guidance for the immunophenotypic analysis of non-neoplastic
More informationProposals of B cells standard immunophenotyping in mature B cell non-hodgkin lymphomas
Clinical immunology Proposals of B cells standard immunophenotyping in mature B cell non-hodgkin lymphomas URSZULA PODSTAWKA, IZABELLA SZCZEPAŃSKA, JOANNA KOPEĆ-SZLĘZAK Department of Hematological Cytobiology,
More informationRef: CYT-MM-MRD. For Research Use Only. Not for use in diagnostic procedures
Ref: CYT-MM-MRD For Research Use Only. Not for use in diagnostic procedures MM MRD VIALS AND COMPENSATION TUBES ARE LYOPHILIZED PRODUCTS. READ CAREFULLY THE FOLLOWING INSTRUCTIONS FOR RECONSTITUTION: The
More informationMinimal Residual Disease assessment in Multiple Myeloma by Next-Generation Sequencing
Minimal Residual Disease assessment in Multiple Myeloma by Next-Generation Sequencing Prof Hervé AVET-LOISEAU, : MD, PhD Institut Universitaire du Cancer Toulouse, France MRD Meta-Analysis in Myeloma Nikhil
More informationChallenges for Flow Cytometry in Regulated Bioanalysis
Challenges for Flow Cytometry in Regulated Bioanalysis Minesh Patel Merck Millipore Discovery & Development Solutions. Oxford, UK. Overview Flow cytometry principles Current uses and regulatory environments
More informationADAPTIVE BIOTECHNOLOGIES DIAGNOSTIC PORTAL: ACCOUNT LOGIN
ADAPTIVE BIOTECHNOLOGIES DIAGNOSTIC PORTAL: ACCOUNT LOGIN 1. Create an account. To set up your account for our online order entry and reporting system, please go to: https://diagnostics.adaptivebiotech.com/account/login.
More information1. INTENDED USE CD71 (L01.1) Form Catalog No. FITC APC Applications IVD 2. COMPOSITION Becton, Dickinson and Company BD Biosciences
2/2014 23-7076-02 IVD CD71 (L01.1) Monoclonal mouse anti-human reagent for identification of cells expressing CD71 antigen Form Catalog No. FITC 333151 APC 337447 BD, BD Logo and all other trademarks are
More informationValidation of Cell-based Fluorescence Assays: Practice Guidelines from the ICSH and ICCS Part III Analytical Issues
Cytometry Part B (Clinical Cytometry) 84B:291 308 (2013) Validation of Cell-based Fluorescence Assays: Practice Guidelines from the ICSH and ICCS Part III Analytical Issues Shabnam Tanqri, 1 * Horacio
More informationADAPTIVE BIOTECHNOLOGIES DIAGNOSTIC PORTAL: ACCOUNT LOGIN
ACCOUNT LOGIN 1. Create an account. To set up your account for our online order entry and reporting system, please go to: https://diagnostics.adaptivebiotech.com/account/login. After signing up, please
More informationCytomics in Action: Cytokine Network Cytometry
Cytomics in Action: Cytokine Network Cytometry Jonni S. Moore, Ph.D. Director, Clinical and Research Flow Cytometry and PathBioResource Associate Professor of Pathology & Laboratory Medicine University
More informationSAMPLE. Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline Third Edition
October 2014 Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline Third Edition This document provides guidance for evaluating the precision performance of quantitative measurement
More informationGuidelines for the diagnosis of Multiple Myeloma Ass.lec.: Dr. Karam T. Agha M.Sc.Pathology
Guidelines for the diagnosis of Multiple Myeloma 2014 By:British Committee for Standards in Haematology (BCSH) Ass.lec.: Dr. Karam T. Agha M.Sc.Pathology Diagnosis, prognostic factors and disease monitoring
More informationPractical Guidelines and Tips for Sensitive and Accurate Identification of PNH Clones
Practical Guidelines and Tips for Sensitive and Accurate Identification of PNH Clones AFCG Meeting Nov 28 Dec 1, 2013 Wellington, New Zealand Andrea Illingworth, MS, H(ASCP), QCYM Dahl-Chase Diagnostic
More informationSAMPLE. Enumeration of Immunologically Defined Cell Populations by Flow Cytometry; Approved Guideline Second Edition
May 2007 Enumeration of Immunologically Defined Cell Populations by Flow Cytometry; Approved Guideline Second Edition This document provides guidance for the immunophenotypic analysis of non-neoplastic
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #70: Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Management of Chronic Conditions
More information1 st European Myeloma Network Meeting
PRELIMINARY PROGRAM 1 st European www.emn2018.com TIMETABLE Thursday, April 19, 2018 Friday, April 20, 2018 Saturday, April 21, 2018 8.00-9.00 MEET THE EXPERTS 8.00-9.00 MEET THE EXPERTS 11.30-11.40 OPENING
More informationSeptember 8, General Comments:
September 8, 2009 AMP Comments on the draft report from the Agency for Healthcare Research and Quality (AHRQ): AHRQ Draft Report on Quality, Regulation and Clinical Utility of Laboratorydeveloped Tests.
More informationProject Proposal Form
Project Proposal Form Date: Submitter contact information: Name: Organization: Phone number: E-mail: Project Submission Proposed Title: Proposed product will be (check one): (See Part 3 for a detailed
More informationBIMM18 Dec 20 th - Flow cytometry in clinical diagnostics
BIMM18 Dec 20 th - Flow cytometry in clinical diagnostics I. B cell leukemia and lymphomas Immunophenotyping as part of the diagnostic work- up of hematologic malignancies offers a rapid and effective
More informationA Risk-based Approach for In Vitro Companion Diagnostics Device FDA Approval Process Associated with Therapies that have Breakthrough Designation
A Risk-based Approach for In Vitro Companion Diagnostics Device FDA Approval Process Associated with Therapies that have Breakthrough Designation A Risk-based Approach for In Vitro Companion Diagnostics
More informationA Report on the Molly and David Bloom Chair in Multiple Myeloma Research at the Princess Margaret Cancer Centre
A Report on the Molly and David Bloom Chair in Multiple Myeloma Research at the Princess Margaret Cancer Centre April 2013 Table of Contents 1 Introduction 2 Your Support 3 Thank you 10 The Princess Margaret
More informationFLOW CYTOMETRY IN CLINICAL DIAGNOSIS 4TH
FLOW CYTOMETRY IN CLINICAL DIAGNOSIS 4TH CONTRIBUTORS Patricia Aoun, MD Associate Professor of Pathology Dept. of Pathology and Microbiology University of Nebraska Medical Center Omaha NE Kenneth A. Ault,
More informationIncorporating New, Bright Fluorochromes into Multicolor Panel Design
Incorporating New, Bright Fluorochromes into Multicolor Panel Design Maria C. Jaimes, MD Senior Staff Scientist BD Biosciences 23-14684-00 Overview Multicolor flow: successful application prerequisites
More informationThe diagnosis and classification of plasma cell dyscrasias
Quantitation of Plasma Cells in Bone Marrow Aspirates by Flow Cytometric Analysis Compared With Morphologic Assessment Kristi J. Smock, MD; Sherrie L. Perkins, MD, PhD; David W. Bahler, MD, PhD Context.
More informationZAP-70 by Flow Cytometry: A Comparison of Different Antibodies, Anticoagulants, and Methods of Analysis
Cytometry Part B (Clinical Cytometry) 70B:235 241 (2006) ZAP-70 by Flow Cytometry: A Comparison of Different Antibodies, Anticoagulants, and Methods of Analysis O. G. Best, R. E. Ibbotson, A. E. Parker,
More informationdetection limit of cytomorphological techniques detection limit of immunophenotyping and PCR techniques cure follow-up in years
relative frequency of leukemic cells 1 10-1 10-2 10-3 10-4 10-5 10-6 10-7 0 Detection of minimal residual disease (MRD) detection limit of cytomorphological techniques detection limit of immunophenotyping
More informationTECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT
Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise
More informationPRINCIPLES OF THE PROCEDURE
CD19 For In Vitro Diagnostic use Fluorochrome Reference Clon Isotype Format µl/test FITC CYT-19F6 HIB19 IgG1 1 ml/200 test 5 PerCP-Cyanine5.5 CYT-19C8 HIB19 IgG1 150ul/50 test 3 PE-Cyanine5 CYT-19C3 HIB19
More informationMolecular Diagnosis Challenges & Solutions. Using Molecular Kits or Laboratory Developed Tests (Home Brew), Emphasis on Validation
Using Molecular Kits or Laboratory Developed Tests (Home Brew), Emphasis on Validation Molecular Diagnosis Challenges & Solutions Behzad Poopak, DCLS PhD Tehran Medical Branch- Islamic Azad University
More informationLaboratory Accreditation Test Validation: A Brave New World for Anatomic Pathology
Laboratory Accreditation Test Validation: A Brave New World for Anatomic Pathology Francis E. Sharkey, MD, FCAP University of Texas Health Science Center, San Antonio, TX Richard W. Brown, MD, FCAP Memorial
More informationFlow cytometry has become an increasingly important
9-Color and 10-Color Flow Cytometry in the Clinical Laboratory Brent Wood, MD, PhD Context. The development of commercial flow cytometers capable of detecting more than 10 simultaneous fluorescent signals
More informationEuroFlow: Resetting leukemia and lymphoma immunophenotyping. Basis for companion diagnostics and personalized medicine
Leukemia (2012) 26, 1899 1907 & 2012 Macmillan Publishers Limited All rights reserved 0887-6924/12 www.nature.com/leu EDITORIAL EuroFlow: Resetting leukemia and lymphoma immunophenotyping. Basis for companion
More informationB-ALL Minimal Residual Disease Flow Cytometry. An Application of a Novel Method for Optimization of a Single-Tube Model
B-ALL Minimal Residual Disease Flow Cytometry An Application of a Novel Method for Optimization of a Single-Tube Model Aaron C. Shaver, MD PhD, 1 Bruce W. Greig, MT(ASCP), CCy, 1 Claudio A. Mosse, MD,
More informationTechnical Assessment (TA) Summary Form (M00116)
Technical Assessment (TA) Summary Form (M00116) Please complete the following 2 table summarization of the dossier. Table 1. Summary of Evidence Validation Element For each cell below, please provide the
More informationFlow Cytometry In Clinical Diagnosis
Flow Cytometry In Clinical Diagnosis If you are searching for the ebook Flow Cytometry in Clinical Diagnosis in pdf form, in that case you come on to loyal website. We presented the full version of this
More informationMass Cytometry: A new platform for single cell characterization Marie Iannone Biological Sciences Research Triangle Park, NC
Mass Cytometry: A new platform for single cell characterization Marie Iannone Biological Sciences Research Triangle Park, NC ELRIG, Ware How does mass cytometry progress state of the art single cell analysis?
More informationLDT Review: The New York Experience
LDT Review: The New York Experience APHL Meeting, Indianapolis, May 21, 2015 Erasmus Schneider, Wadsworth Center, NYS DOH erasmus.schneider@health.ny.gov May 21, 2015 May 21, 2015 2 As the New York State
More informationMarch 19, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852
March 19, 2018 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852 RE: Docket No. FDA-2017-D-6765; Draft Guidance for Industry and Food
More informationSAMPLE. Establishing and Verifying an Extended Measuring Interval Through Specimen Dilution and Spiking
1st Edition EP34 Establishing and Verifying an Extended Measuring Interval Through Specimen Dilution and Spiking It is often medically necessary to provide results for specimens with concentrations above
More informationMultiple Myeloma Highlights From the 2015 ASCO Annual Meeting and the 20 th Congress of EHA
Multiple Myeloma Highlights From the 2015 ASCO Annual Meeting and the 20 th Congress of EHA July 13, 2015 Welcome and Introductions Anne Quinn Young, MPH Multiple Myeloma Research Foundation Norwalk, CT
More informationEstablishing Quality Control Target Values and Standard Deviations for Hematology Instrumentation
Establishing Quality Control Target Values and Standard Deviations for Hematology Instrumentation For informational purposes only. WHO REQUIRES IT AND WHAT THEY REQUIRE Regulatory agencies require the
More informationNavios EX FLOW CYTOMETER POWERFUL, DEPENDABLE CLINICAL FLOW CYTOMETRY
Navios EX FLOW CYTOMETER POWERFUL, DEPENDABLE CLINICAL FLOW CYTOMETRY BECAUSE EVERY EVENT MATTERS The Navios EX flow cytometer offers a solution for advanced cytometry applications optimized for the clinical
More informationChallenges in receptor occupancy determination assays by flow cytometry in drug development
Challenges in receptor occupancy determination assays by flow cytometry in drug development DATE 17 November 2016 PRESENTED BY Martine Broekema, Ph.D. Associated Director of Bioanalytical Sciences Large
More informationHot Topic. Disclosures. None
Hot Topic Multiple Myeloma Testing at Mayo Medical Laboratories HOT TOPIC / 2017 MFMER 1 Our speaker for this program is Dragan Jevremovic, MD, PhD Assistant Professor, Division of Hematopathology at Mayo
More informationAutomated and Simplified Identification of Normal and Abnormal Plasma Cells in Multiple Myeloma by Flow Cytometry
Cytometry Part B (Clinical Cytometry) 00:00 00 (2017) Original Article Automated and Simplified Identification of Normal and Abnormal Plasma Cells in Multiple Myeloma by Flow Cytometry Elina Alaterre,
More informationThe Emergence of Flow Cytometry as a Routine Diagnostic Testing Technology Right Here in Our Own Back Yard! Mike Reed February 2013
The Emergence of Flow Cytometry as a Routine Diagnostic Testing Technology Right Here in Our Own Back Yard! Mike Reed February 2013 Overview Danaher designs, manufactures, and markets innovative products
More informationbioanalytical challenge Patrick Bennett PPD Biomarker Laboratories November 2015
Biomarkers: Not just another bioanalytical challenge Patrick Bennett PPD Biomarker Laboratories a o November 2015 European Bioanalysis Forum 1 Biomarker Life Cycle Discovery Preclinical... Clinical Testing
More information